These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30947414)

  • 1. Optimal dengue vaccination strategies of seropositive individuals.
    Shim E
    Math Biosci Eng; 2019 Feb; 16(3):1171-1189. PubMed ID: 30947414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report.
    Wilder-Smith A; Smith PG; Luo R; Kelly-Cirino C; Curry D; Larson H; Durbin A; Chu M; Tharmaphornpilas P; Ng LC; Sartori AMC; Luna EJA; Gubler DJ; España G; Yoon IK; Flasche S
    Vaccine; 2019 Aug; 37(36):5137-5146. PubMed ID: 31377079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
    Lee JS; Lourenço J; Gupta S; Farlow A
    Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
    El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
    Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Math Med Biol; 2021 Mar; 38(1):1-27. PubMed ID: 32671383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
    Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
    Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
    Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
    Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
    Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
    Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement.
    Tang B; Huo X; Xiao Y; Ruan S; Wu J
    Theor Biol Med Model; 2018 Sep; 15(1):13. PubMed ID: 30173664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.